Novo Nordisk A/S - ADR

Name: Novo Nordisk A/S - ADR Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Novo Nordisk A/S - ADR

Stock Card

$44.56

$-0.60 (-1.33%)

As on 09-Sep-2026 16:29EDT

Market cap

$210,043 Mln

Revenue (TTM)

$329,431 Mln

P/E Ratio

11.6

P/B Ratio

5.8

Div. Yield

3.8 %

Novo Nordisk A/S - ADR Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 44.52 High: 45.40

52 Week Range

Low: 35.13 High: 64.16

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$46,897 Mln
ROE

0.6 %
ROCE

35.9 %
Industry P/E

37.91
EV/EBITDA

9.4
Debt to Equity

0.6
Book Value

$--
EPS

$26.2
Face value

--
Shares outstanding

3,346,158,124

10 Years Aggregate

CFO

Kr.545,605.00 Mln

EBITDA

Kr.626,068.00 Mln

Net Profit

Kr.444,078.00 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Novo Nordisk A/S - ADR	-12.4	-5.7	8.6	-17.9	-23.0	-2.4	6.8
BSE Sensex^*	-11.7	-4.8	1.1	-7.9	3.9	5.1	10.0

As on 09-Sep-2026 | *As on 10-Sep-2026

Company	2025	2024	2023	2022	2021	2020	2019
Novo Nordisk A/S - ADR	-40.9	-16.7	52.9	20.8	63.5	23.3	28.7
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Novo Nordisk A/S - ADR

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and... Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Read more

President, CEO & Member of Management Board

Mr. Lars Fruergaard Jorgensen
President, CEO & Member of Management Board

Mr. Lars Fruergaard Jorgensen
Headquarters

Bagsvaerd
Website

https://www.novonordisk.com

FAQs for Novo Nordisk A/S - ADR

What is the current share price of Novo Nordisk A/S - ADR Today?

The share price of Novo Nordisk A/S - ADR is $44.56 (NYSE) as of 09-Sep-2026 16:29 EDT. Novo Nordisk A/S - ADR has given a return of -23.02% in the last 3 years.

What is the current PB & PE ratio of Novo Nordisk A/S - ADR?

The P/E ratio of Novo Nordisk A/S - ADR is 11.64 times as on 04-Sep-2026, a 69 discount to its peers’ median range of 37.91 times.
The P/B ratio of Novo Nordisk A/S - ADR is 5.81 times as on 04-Sep-2026, a 24 discount to its peers’ median range of 7.69 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	2.21	1.17
2024	3.80	2.67
2023	5.54	4.35
2022	11.02	7.33
2021	10.76	7.26

What is the 52 Week High and Low of Novo Nordisk A/S - ADR?

The 52-week high and low of Novo Nordisk A/S - ADR are Rs 64.16 and Rs 35.13 as of 10-Sep-2026.

What is the market cap of Novo Nordisk A/S - ADR?

Novo Nordisk A/S - ADR has a market capitalisation of $ 210,043 Mln as on 04-Sep-2026. As per SEBI classification, it is a company.

Should I invest in Novo Nordisk A/S - ADR?

Before investing in Novo Nordisk A/S - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.